Patents by Inventor Jien-Heh Tien
Jien-Heh Tien has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230373990Abstract: Provided herein is a bulk composition comprising the trihydrate form of (3S, 4R, 3?R)-6-[4-(4-amino-5-chloro-2-methoxy-benzoylamino)-3-methoxy-piperidin-1-yl]-hexanoic acid 1-azabicyclo[2.2.2]oct-3?-yl ester di-hydrochloride salt. Provided are also pharmaceutical compositions and dosage forms comprising the trihydrate form, and methods and uses for treating a gastrointestinal disorder in a subject with the trihydrate form. In some embodiments, the gastrointestinal disorder is gastroesophageal reflux disease (GERD), dyspepsia (such as functional dyspepsia or functional motility disorder), gastroparesis, paralytic ileus, post-operative ileus, emesis, nausea, heartburn, intestinal pseudo-obstruction, irritable bowel syndrome (IBS), constipation, enteral feeding intolerance (EFI), or esophagitis. In some embodiments, the gastrointestinal disorder is post-operative ileus, chronic grass sickness, constipation, megacolon, gastritis, gastrointestinal stasis, or abomasal emptying defect.Type: ApplicationFiled: August 1, 2023Publication date: November 23, 2023Inventors: Pascal Jean DRUZGALA, Peter MILNER, Jien Heh TIEN
-
Patent number: 11643409Abstract: Provided herein is a bulk composition comprising the trihydrate form of (3S, 4R, 3?R)-6-[4-(4-amino-5-chloro-2-methoxy-benzoylamino)-3-methoxy-piperidin-1-yl]-hexanoic acid 1-azabicyclo[2.2.2]oct-3?-yl ester di-hydrochloride salt. Provided are also pharmaceutical compositions and dosage forms comprising the trihydrate form, and methods and uses for treating a gastrointestinal disorder in a subject with the trihydrate form. In some embodiments, the gastrointestinal disorder is gastroesophageal reflux disease (GERD), dyspepsia (such as functional dyspepsia or functional motility disorder), gastroparesis, paralytic ileus, post-operative ileus, emesis, nausea, heartburn, intestinal pseudo-obstruction, irritable bowel syndrome (IBS), constipation, enteral feeding intolerance (EFI), or esophagitis. In some embodiments, the gastrointestinal disorder is post-operative ileus, chronic grass sickness, constipation, megacolon, gastritis, gastrointestinal stasis, or abomasal emptying defect.Type: GrantFiled: August 12, 2022Date of Patent: May 9, 2023Assignee: Renexxion, LLCInventors: Pascal Jean Druzgala, Jien Heh Tien
-
Publication number: 20220380361Abstract: Provided herein is a bulk composition comprising the trihydrate form of (3S, 4R, 3?R)-6-[4-(4-amino-5-chloro-2-methoxy-benzoylamino)-3-methoxy-piperidin-1-yl]-hexanoic acid 1-azabicyclo[2.2.2]oct-3?-yl ester di-hydrochloride salt. Provided are also pharmaceutical compositions and dosage forms comprising the trihydrate form, and methods and uses for treating a gastrointestinal disorder in a subject with the trihydrate form. In some embodiments, the gastrointestinal disorder is gastroesophageal reflux disease (GERD), dyspepsia (such as functional dyspepsia or functional motility disorder), gastroparesis, paralytic ileus, post-operative ileus, emesis, nausea, heartburn, intestinal pseudo-obstruction, irritable bowel syndrome (IBS), constipation, enteral feeding intolerance (EFI), or esophagitis. In some embodiments, the gastrointestinal disorder is post-operative ileus, chronic grass sickness, constipation, megacolon, gastritis, gastrointestinal stasis, or abomasal emptying defect.Type: ApplicationFiled: August 12, 2022Publication date: December 1, 2022Inventors: Pascal Jean DRUZGALA, Peter MILNER, Jien Heh TIEN
-
Publication number: 20210355116Abstract: Provided herein are methods of producing the trihydrate form of (3S, 4R, 3?R)-6-[4-(4-amino-5-chloro-2-methoxy-benzoylamino)-3-methoxy-piperidin-1-yl]-hexanoic acid 1-azabicyclo[2.2.2]oct-3?-yl ester di-hydrochloride salt.Type: ApplicationFiled: April 30, 2021Publication date: November 18, 2021Inventors: Pascal Jean DRUZGALA, Peter MILNER, Jien Heh TIEN, Jinun-Ban YEH, Yen-Wei LI, Yen-Chi SU
-
Patent number: 10570127Abstract: Provided herein is a bulk composition comprising the trihydrate form of (3S, 4R, 3?R)-6-[4-(4-amino-5-chloro-2-methoxy-benzoylamino)-3-methoxy-piperidin-1-yl]-hexanoic acid 1-azabicyclo[2.2.2]oct-3?-yl ester di-hydrochloride salt. Provided are also pharmaceutical compositions and dosage forms comprising the trihydrate form, and methods and uses for treating a gastrointestinal disorder in a subject with the trihydrate form. In some embodiments, the gastrointestinal disorder is gastroesophageal reflux disease (GERD), dyspepsia (such as functional dyspepsia or functional motility disorder), gastroparesis, paralytic ileus, post-operative ileus, emesis, nausea, heartburn, intestinal pseudo-obstruction, irritable bowel syndrome (IBS), constipation, enteral feeding intolerance (EFI), or esophagitis. In some embodiments, the gastrointestinal disorder is post-operative ileus, chronic grass sickness, constipation, megacolon, gastritis, gastrointestinal stasis, or abomasal emptying defect.Type: GrantFiled: November 5, 2018Date of Patent: February 25, 2020Assignee: Renexxion, LLCInventors: Pascal Jean Druzgala, Jien Heh Tien
-
Patent number: 10144692Abstract: This invention discloses a method of making vitamin K1. The mentioned method of making vitamin K1 comprises performing a first one-pot synthesis with base catalyst, performing a first hydrolysis, performing a substitution, and performing a second one-pot synthesis without metal oxidant. The starting material of this invention is stable 2-methyl-1,4-naphthoquinone. Preferably, this invention provides a method of making vitamin K1 efficiently on simplifying the operation and decreasing the side-product. More preferably, without metal residue, the vitamin K1 of this invention is without metal residue and more safety for clinical application.Type: GrantFiled: October 16, 2014Date of Patent: December 4, 2018Assignee: SUNNY PHARMTECH INC.Inventors: Jien-Heh Tien, Chu-Yi Pang, Nai-Hsuan Hsu
-
Publication number: 20170260117Abstract: This invention discloses a method of making vitamin K1. The mentioned method of making vitamin K1 comprises performing a first one-pot synthesis with base catalyst, performing a first hydrolysis, performing a substitution, and performing a second one-pot synthesis without metal oxidant. The starting material of this invention is stable 2-methyl-1,4-naphthoquinone. Preferably, this invention provides a method of making vitamin K1 efficiently on simplifying the operation and decreasing the side-product. More preferably, without metal residue, the vitamin K1 of this invention is without metal residue and more safety for clinical application.Type: ApplicationFiled: October 16, 2014Publication date: September 14, 2017Applicant: Sunny Pharmtech Inc.Inventors: Jien-Heh Tien, Chu-Yi Pang, Nai-Hsuan Hsu
-
Patent number: 9115160Abstract: This invention discloses a solvent-free process for the preparation of cyclophosphamide. According to this invention, there is no solvent used during the reaction step for preparing cyclophosphamide, so that the total volume of the reaction for preparing cyclophosphamide can be reduced and the manufacture of cyclophosphamide can become more efficient. Furthermore, the above solvent-free process for the preparation of cyclophosphamide is more simply operated, more economic, and more environmental friendly than the preparation of cyclophosphamide in the prior art.Type: GrantFiled: August 29, 2013Date of Patent: August 25, 2015Assignee: SUNNY PHARMTECH INC.Inventors: Jien-Heh Tien, Pi-Shan Chiang
-
Patent number: 8809581Abstract: The present invention provides a method for making 6-aminocaproic acid as an active pharmaceutical ingredient. The method comprises: performing a hydrolysis procedure to have ?-caprolactam react with acid or base to generate a first reaction mixture, performing a modification procedure to have a solubility regulating agent reacts with 6-aminocaproic acid in the first reaction mixture to form a second reaction mixture including an aminocaproic acid intermediate, performing a separation procedure to have the intermediate separated from the second reaction mixture and performing a hydrogenation procedure to have the aminocaproic acid intermediate hydrogenated to form a 6-aminocaproic acid product.Type: GrantFiled: October 25, 2012Date of Patent: August 19, 2014Assignee: Sunny Pharmtech Inc.Inventors: Jien-Heh Tien, Chu-yi Pang
-
Publication number: 20140066654Abstract: This invention discloses a solvent-free process for the preparation of cyclophosphamide. According to this invention, there is no solvent used during the reaction step for preparing cyclophosphamide, so that the total volume of the reaction for preparing cyclophosphamide can be reduced and the manufacture of cyclophosphamide can become more efficient. Furthermore, the above solvent-free process for the preparation of cyclophosphamide is more simply operated, more economic, and more environmental friendly than the preparation of cyclophosphamide in the prior art.Type: ApplicationFiled: August 29, 2013Publication date: March 6, 2014Applicant: Sunny Pharmtech Inc.Inventors: Jien-Heh Tien, Pi-Shan Chiang
-
Publication number: 20140039219Abstract: The present invention provides a method for making 6-aminocaproic acid as an active pharmaceutical ingredient. The method comprises: performing a hydrolysis procedure to have ?-caprolactam react with acid or base to generate a first reaction mixture, performing a modification procedure to have a solubility regulating agent reacts with 6-aminocaproic acid in the first reaction mixture to form a second reaction mixture including an aminocaproic acid intermediate, performing a separation procedure to have the intermediate separated from the second reaction mixture and performing a hydrogenation procedure to have the aminocaproic acid intermediate hydrogenated to form a 6-aminocaproic acid product.Type: ApplicationFiled: October 25, 2012Publication date: February 6, 2014Applicant: Sunny Pharmtech Inc.Inventors: Jien-Heh Tien, Chu-yi Pang
-
Publication number: 20070060640Abstract: The invention comprises compounds of Formula 1: wherein, R1 is independently H or halogen; R2 is, for example, H or —R10—NR11R12, and wherein R10 is C1-C6 alkyl, and R11 and R12 are independently H, C1-C4 alkyl, and hydrates, solvates, salts and tautomers thereof. The invention further comprises methods for making the compounds of the invention and methods for making compounds useful in the treatment or prevention of cardiac arrhythmia from the compounds of the invention.Type: ApplicationFiled: July 14, 2006Publication date: March 15, 2007Applicant: ARYX THERAPEUTICSInventors: Pascal Druzgala, Jien-Heh Tien, Arthur Cooper, Cyrus Becker
-
Publication number: 20060128962Abstract: The invention relates to a process for preparing quinoline-substituted carbonate and carbamate compounds, which are important intermediates in the synthesis of 6-O-substituted macrolide antibiotics. The process employs metal-catalyzed coupling reactions to provide a carbonate or carbamate of formula (I) or (II) or a substrate that can be reduced to obtain the same.Type: ApplicationFiled: February 6, 2006Publication date: June 15, 2006Inventors: Michael Allen, Ramiya Premchandran, Sou-Jen Chang, Stephen Condon, John DeMattei, Steven King, Lawrence Kolaczkowski, Sukumar Manna, Paul Nichols, Hemant Patel, Subhash Patel, Daniel Plata, Eric Stoner, Jien-Heh Tien, Steven Wittenberger
-
Publication number: 20050250795Abstract: Methods and novel intermediates for the preparation of acyclic nucleoside derivatives of the formula: where one of R1 and R2 is an amino acid acyl group and the other of R1 and R2 is a —C(O)C3-C21 saturated or monounsaturated, optionally substituted alkyl and R3 is OH or H; or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 18, 2005Publication date: November 10, 2005Applicant: Medivir ABInventors: M. Leanna, Steven Hannick, Michael Rasmussen, Jien-Heh Tien, Lakshmi Bhagavatula, Pulla Singam, Bradley Gates, Lawrence Kolaczkowski, Ramesh Patel, Greg Wayne, Greg Lannoye, Weijiang Zhang, Zhenping Tian, Kirill Lukin, Bikshandarkoil Narayanan, David Riley, Howard Morton, Sou-Jen Chang, Cynthia Curty, Daniel Plata, John Bellettini, Bhadra Shelat, Tiffany Spitz, Cheng-Xi Yang
-
Patent number: 5892008Abstract: The claimed invention provides a novel method of preparing 6-O-methyl erythromycin A. The process comprises the steps of reducing the 9-keto group of erythromycin A to form a 9-hydroxy erythromycin A, protecting the 9-, 2'-, and/or 4"-hydroxyl groups of erythromycin A, selectively methylating the 6-position of the 9-hydroxy erythromycin A derivative, deprotecting the hydroxyl groups and oxidizing the 9-hydroxyl to afford 6-O-methyl erythromycin A.Type: GrantFiled: December 16, 1997Date of Patent: April 6, 1999Assignee: Abbott LaboratoriesInventors: Yi-Yin Ku, David A. Riley, Elaine C. Lee, Jien-Heh Tien